Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 04-05-2024 | Insulins | Research article

Lipidomic signatures in Colombian adults with metabolic syndrome

Authors: María Fernanda Serna, Milton Fabián Suarez-Ortegón, Eliécer Jiménez-Charris, Isabella Echeverri, Mónica P. Cala, Mildrey Mosquera

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2024

Abstract

Background and Aims

Metabolic syndrome (MetS) comprises a set of risk factors that contribute to the development of chronic and cardiovascular diseases, increasing the mortality rate. Altered lipid metabolism is associated with the development of metabolic disorders such as insulin resistance, obesity, atherosclerosis, and metabolic syndrome; however, there is a lack of knowledge about lipids compounds and the lipidic pathways associated with this condition, particularly in the Latin-American population. Innovative approaches, such as lipidomic analysis, facilitate the identification of lipid species related to these risk factors. This study aimed to assess the plasma lipidome in subjects with MetS.

Methods

This correlation study included healthy adults and adults with MetS. Blood samples were analyzed. The lipidomic profile was determined using an Agilent Technologies 1260 liquid chromatography system coupled to a Q-TOF 6545 quadrupole mass analyzer with electrospray ionization. The main differences were determined between the groups.

Results

The analyses reveal a distinct lipidomic profile between healthy adults and those with MetS, including increased concentrations of most identified glycerolipids -both triglycerides and diglycerides- and decreased levels of ether lipids and sphingolipids, especially sphingomyelins, in MetS subjects. Association between high triglycerides, waist circumference, and most differentially expressed lipids were found.

Conclusion

Our results demonstrate dysregulation of lipid metabolism in subjects with Mets, supporting the potential utility of plasma lipidome analysis for a deeper understanding of MetS pathophysiology.

Available only for authorised users

Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?, (in eng). Diabetes Care. 2004;27(11):2676–81. https://doi.org/10.2337/diacare.27.11.2676.CrossRefPubMed

Alberti KGMM et al., Harmonizing the Metabolic Syndrome. Circulation. 2009;120(16):1640–1645, 2009/10/20. doi: https://doi.org/10.1161/CIRCULATIONAHA.109.192644.

Eberly LE, et al. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial, (in eng). Diabetes Care. 2006;29(1):123–30. https://doi.org/10.2337/diacare.29.1.123.CrossRefPubMed

Escobedo J et al., Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study, (in eng), Cardiovasc Diabetol. 2009;8:52. doi: https://doi.org/10.1186/1475-2840-8-52.

Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. “The prevalence of metabolic syndrome in various populations,” (in eng). Am J Med Sci. Jun2007;333(6):362–71. https://doi.org/10.1097/MAJ.0b013e318065c3a1.CrossRefPubMed

Monnerie S, Comte B, Ziegler D, Morais JA, Pujos-Guillot E, Gaudreau P. Metabolomic and Lipidomic Signatures of Metabolic Syndrome and its Physiological Components in Adults: A Systematic Review. Scientific Reports. 2020;10(1):669, 2020/01/20. doi: https://doi.org/10.1038/s41598-019-56909-7.

Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms, (in eng). Am Heart J, 2005;149(1):33–45, 2005/01//, https://doi.org/10.1016/j.ahj.2004.07.013.

Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B. Inflammation as a Link between Obesity and Metabolic Syndrome, (in eng), J Nutr Metab, 2012;2012:476380. doi: https://doi.org/10.1155/2012/476380.

Wymann MP, Schneiter R. Lipid signalling in disease. Nature Rev Mol Cell Biol. 2008;9(2):162–176, 2008/02/01. doi: https://doi.org/10.1038/nrm2335.

10.

Yin X, et al. “Lipidomic profiling identifies signatures of metabolic risk,” (in eng). EBioMedicine. Jan2020;51:102520. https://doi.org/10.1016/j.ebiom.2019.10.046.CrossRefPubMed

11.

Ho JE, et al. “Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes,” (in eng). PLoS ONE. 2016;11(2):e0148361. https://doi.org/10.1371/journal.pone.0148361.CrossRefPubMedPubMedCentral

12.

Kulkarni H, Mamtani M, Blangero J, Curran JE. “Lipidomics in the Study of Hypertension in Metabolic Syndrome,” (in eng). Curr Hypertens Rep. Jan2017;19(1):7. https://doi.org/10.1007/s11906-017-0705-6.CrossRefPubMed

13.

Lydic TA, Goo Y-H. “Lipidomics unveils the complexity of the lipidome in metabolic diseases,” (in eng). Clin Transl Med. 2018;7(1):4–4. https://doi.org/10.1186/s40169-018-0182-9.CrossRefPubMedPubMedCentral

14.

Suárez-Ortegón MF, Arbeláez A, Mosquera M, Moreno-Navarrete JM, Aguilar-Plata C, Fernández-Real JM. Circulating Hepcidin Is Independently Associated with Systolic Blood Pressure in Apparently Healthy Individuals. Arch Med Res. 2015;46(6):507–513, 2015/08/01/. https://doi.org/10.1016/j.arcmed.2015.07.007.

15.

Yero J, Iglesias Á, González D. Utilidad del índice HOMA-IR con una sola determinación de insulinemia para diagnosticar resistencia insulínica. Revista Cubana de Endocrinología, 2011;22:69–77, 08/01.

16.

Armstrong RA. When to use the Bonferroni correction. Ophthal Physiol Optics. 2014;34(5):502–508, 2014/09/01. doi: https://doi.org/10.1111/opo.12131.

17.

Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods, (in eng). Am J Public Health. 1996;86(5):726–8. https://doi.org/10.2105/ajph.86.5.726.CrossRefPubMedPubMedCentral

18.

Blaženović I, Kind T, Ji J, Fiehn O. Software Tools and Approaches for Compound Identification of LC-MS/MS Data in Metabolomics, (in eng), Metabolites. 2018;8(2), doi: https://doi.org/10.3390/metabo8020031.

19.

Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst, (in eng). Nat Protoc. 2011;6(6):743–60. https://doi.org/10.1038/nprot.2011.319.CrossRefPubMed

20.

Kulkarni H et al. Plasma lipidome is independently associated with variability in metabolic syndrome in Mexican American families. J Lipid Res, 2014;55(5):939–946, 2014/05/01/. https://doi.org/10.1194/jlr.M044065.

21.

Ramakrishanan N, Denna T, Devaraj S, Adams-Huet B, Jialal I. Exploratory lipidomics in patients with nascent Metabolic Syndrome, (in eng). J Diabetes Complications. 2018;32(8):791–4. https://doi.org/10.1016/j.jdiacomp.2018.05.014.CrossRefPubMed

22.

Gong LL et al. Discovery of metabolite profiles of metabolic syndrome using untargeted and targeted LC-MS based lipidomics approach, (in eng), J Pharm Biomed Anal. 2020;177:112848, doi: https://doi.org/10.1016/j.jpba.2019.112848.

23.

Pan W, et al. Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes, (in eng). Coron Artery Dis. 2014;25(3):230–5. https://doi.org/10.1097/mca.0000000000000079.CrossRefPubMed

24.

Majumdar I, Mastrandrea LD. Serum sphingolipids and inflammatory mediators in adolescents at risk for metabolic syndrome. Endocrine, 2012;41(3):442–449, 2012/06/01. doi: https://doi.org/10.1007/s12020-011-9589-4.

25.

Cowart LA. Sphingolipids: players in the pathology of metabolic disease, (in eng). Trends Endocrinol Metab. 2009;20(1):34–42. https://doi.org/10.1016/j.tem.2008.09.004.CrossRefPubMed

26.

Hanamatsu H et al. Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutrition & Diabetes. 2014;4(10):e141-e141, 2014/10/01. doi: https://doi.org/10.1038/nutd.2014.38.

27.

Xu F, Tavintharan S, Sum CF, Woon K, Lim SC, Ong CN. “Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics,” (in eng). J Clin Endocrinol Metab. 2013;98(6):E1060–5. https://doi.org/10.1210/jc.2012-4132.CrossRefPubMed

28.

Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered Adipose and Plasma Sphingolipid Metabolism in Obesity. Diabetes. 2006;55(9):2579. https://doi.org/10.2337/db06-0330.CrossRefPubMed

29.

Bergman BC, et al. “Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans,” (in eng), American journal of physiology. Endocrinol Metab. 2015;309(4):E398–408. https://doi.org/10.1152/ajpendo.00134.2015.CrossRef

30.

Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79(3):379–84. https://doi.org/10.1093/ajcn/79.3.379.CrossRefPubMed

31.

Tonks KT et al. Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. Obesity. 2016;24(4):908–916, 2016/04/01. https://doi.org/10.1002/oby.21448.

32.

Petersen MC, Shulman GI. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance, (in eng). Trends Pharmacol Sci. 2017;38(7):649–65. https://doi.org/10.1016/j.tips.2017.04.004.CrossRefPubMedPubMedCentral

33.

Kopprasch S, et al. Detection of Independent Associations of Plasma Lipidomic Parameters with Insulin Sensitivity Indices Using Data Mining Methodology, (in eng). PLoS ONE. 2016;11(10):e0164173. https://doi.org/10.1371/journal.pone.0164173.CrossRefPubMedPubMedCentral

34.

Bagheri M et al. A lipidome-wide association study of the lipoprotein insulin resistance index, (in eng), Lipids Health Dis. 2020;19(1):153. doi: https://doi.org/10.1186/s12944-020-01321-8.

35.

Herrera VM, et al. “Interethnic differences in the accuracy of anthropometric indicators of obesity in screening for high risk of coronary heart disease,” (in eng). Int J Obes (Lond). 2009;33(5):568–76. https://doi.org/10.1038/ijo.2009.35.CrossRefPubMed

36.

Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Fernández Ballart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review, (in eng), Public Health Nutr, 2011;14(10):1702–13. doi: https://doi.org/10.1017/s1368980010003320.

37.

Lanas F et al. Risk Factors for Acute Myocardial Infarction in Latin America. Circulation. 2007;115(9):1067–1074, 2007/03/06, doi: https://doi.org/10.1161/CIRCULATIONAHA.106.633552.

38.

Miranda JJ et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO), (in eng), PLoS One. 2013;8(1):e54056. doi: https://doi.org/10.1371/journal.pone.0054056.

39.

Dean JM, Lodhi IJ. Structural and functional roles of ether lipids, (in eng). Protein Cell. 2018;9(2):196–206. https://doi.org/10.1007/s13238-017-0423-5.CrossRefPubMed

40.

Zhang C, et al. Inhibited Insulin Signaling in Mouse Hepatocytes Is Associated with Increased Phosphatidic Acid but Not Diacylglycerol *. J Biol Chem. 2015;290(6):3519–28. https://doi.org/10.1074/jbc.M114.602789.CrossRefPubMed

41.

Pietiläinen KH et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study, (in eng), PLoS One. 2007;2(2):e218. doi: https://doi.org/10.1371/journal.pone.0000218.

42.

Graessler J, Schwudke D, Schwarz PE, Herzog R, Shevchenko A, Bornstein SR. Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients, (in eng), PLoS One. 2009;4(7):e6261. doi: https://doi.org/10.1371/journal.pone.0006261.

43.

da Silva TF, Sousa VF, Malheiro AR, Brites P. The importance of ether-phospholipids: A view from the perspective of mouse models. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822(9):1501–1508, 2012/09/01/. https://doi.org/10.1016/j.bbadis.2012.05.014.

44.

Brosche T, Platt D. The biological significance of plasmalogens in defense against oxidative damage, (in eng). Exp Gerontol. 1998;33(5):363–9. https://doi.org/10.1016/s0531-5565(98)00014-x.CrossRefPubMed

45.

Brosche T. Plasmalogen levels in serum from patients with impaired carbohydrate or lipid metabolism and in elderly subjects with normal metabolic values, (in eng). Arch Gerontol Geriatr. 2001;32(3):283–94. https://doi.org/10.1016/s0167-4943(01)00105-4.CrossRefPubMed

46.

Rasmiena AA, et al. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice, (in eng). Atherosclerosis. 2015;243(2):598–608. https://doi.org/10.1016/j.atherosclerosis.2015.10.096.CrossRefPubMed

47.

Ikuta A, et al. Composition of plasmalogens in serum lipoproteins from patients with non-alcoholic steatohepatitis and their susceptibility to oxidation, (in eng). Clin Chim Acta. 2019;493:1–7. https://doi.org/10.1016/j.cca.2019.02.020.CrossRefPubMed

48.

Mahjoub S, Masrour-Roudsari J. Role of oxidative stress in pathogenesis of metabolic syndrome, (in eng), Caspian J Internal Med. 2012;3(1):386–396, Winter.

49.

van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease, (in eng), Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1558–1572. doi: https://doi.org/10.1016/j.bbamem.2017.04.006.

50.

Rauschert S, et al. Lipidomics Reveals Associations of Phospholipids With Obesity and Insulin Resistance in Young Adults, (in eng). J Clin Endocrinol Metab. 2016;101(3):871–9. https://doi.org/10.1210/jc.2015-3525.CrossRefPubMed

51.

Araki W, Wurtman RJ. Control of membrane phosphatidylcholine biosynthesis by diacylglycerol levels in neuronal cells undergoing neurite outgrowth, (in eng). Proc Natl Acad Sci U S A. 1997;94(22):11946–50. https://doi.org/10.1073/pnas.94.22.11946.CrossRefPubMedPubMedCentral

52.

Lim P, Cornell R, Vance DE. The supply of both CDP-choline and diacylglycerol can regulate the rate of phosphatidylcholine synthesis in HeLa cells, (in eng). Biochem Cell Biol. 1986;64(7):692–8. https://doi.org/10.1139/o86-095.CrossRefPubMed

53.

van der Veen JN, Lingrell S, Vance DE. The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver, (in eng). J Biol Chem. 2012;287(28):23418–26. https://doi.org/10.1074/jbc.M112.381723.CrossRefPubMedPubMedCentral

54.

Kulkarni H, et al. Variability in associations of phosphatidylcholine molecular species with metabolic syndrome in Mexican-American families, (in eng). Lipids. 2013;48(5):497–503. https://doi.org/10.1007/s11745-013-3781-7.CrossRefPubMedPubMedCentral

55.

Syme C, et al. Glycerophosphocholine Metabolites and Cardiovascular Disease Risk Factors in Adolescents: A Cohort Study, (in eng). Circulation. 2016;134(21):1629–36. https://doi.org/10.1161/circulationaha.116.022993.CrossRefPubMed

56.

Liu P et al. The mechanisms of lysophosphatidylcholine in the development of diseases, (in eng), Life Sci. 2020;247:117443. doi: https://doi.org/10.1016/j.lfs.2020.117443.

57.

Barber MN, et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes, (in eng). PLoS ONE. 2012;7(7):e41456. https://doi.org/10.1371/journal.pone.0041456.CrossRefPubMedPubMedCentral

58.

Beyene HB, et al. High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies, (in eng). PLoS Biol. 2020;18(9):e3000870–e3000870. https://doi.org/10.1371/journal.pbio.3000870.CrossRefPubMedPubMedCentral

59.

Pani A et al., Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients. 2020;12(11). doi: https://doi.org/10.3390/nu12113379.

60.

Shirouchi B, et al. Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats, (in eng). J Agric Food Chem. 2008;56(7):2375–9. https://doi.org/10.1021/jf703578d.CrossRefPubMed

61.

Shimizu K, Ida T, Tsutsui H, Asai T, Otsubo K, Oku N. Anti-obesity effect of phosphatidylinositol on diet-induced obesity in mice, (in eng). J Agric Food Chem. 2010;58(21):11218–25. https://doi.org/10.1021/jf102075j.CrossRefPubMed

62.

Stamler CJ, Breznan D, Neville TA, Viau FJ, Camlioglu E, Sparks DL. Phosphatidylinositol promotes cholesterol transport in vivo, (in eng). J Lipid Res. 2000;41(8):1214–21.CrossRefPubMed

63.

Palmano KP, Whiting PH, Hawthorne JN. Free and lipid myo-inositol in tissues from rats with acute and less severe streptozotocin-induced diabetes. Biochem J. 1977;167(1):229–35. https://doi.org/10.1042/bj1670229.CrossRefPubMedPubMedCentral

64.

Meikle PJ, et al. Plasma lipid profiling shows similar associations with prediabetes and type 2 diabetes, (in eng). PLoS ONE. 2013;8(9):e74341. https://doi.org/10.1371/journal.pone.0074341.CrossRefPubMedPubMedCentral

65.

Deidda M et al. Metabolomic approach to profile functional and metabolic changes in heart failure. J Trans Med. 2015;13(1):297, 2015/09/12. doi: https://doi.org/10.1186/s12967-015-0661-3.

Title: Lipidomic signatures in Colombian adults with metabolic syndrome
Authors: María Fernanda Serna
Milton Fabián Suarez-Ortegón
Eliécer Jiménez-Charris
Isabella Echeverri
Mónica P. Cala
Mildrey Mosquera
Publication date: 04-05-2024
Publisher: Springer International Publishing
Keywords: Insulins
Insulins
Obesity
Obesity
Multiple Sclerosis
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2024
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-024-01423-5

Multiple nanotechnological approaches using natural compounds for diabetes management

Diabetes
Review article

Correction: Cardiac angiogenesis enhances by activating Mir-126 and related target proteins in type 2 diabetic rats: rescue combination effect of sodium butyrate and voluntary exercise therapy

Exercise Therapy
Correction

The effect of chamomile consumption on glycemic markers in humans and animals: a systematic review and meta-analysis

Insulins
Review article

The association between gut microbiota and resting metabolic rate in overweight/obese women: a case–control study

Respiratory Microbiota
Research article

Individual, interpersonal, and community factors associated with health outcomes in patients with type 2 diabetes mellitus treated at federally qualified health centers

Type 2 Diabetes
Research article

The impact of sodium-glucose cotransporter inhibitors on gut microbiota: a scoping review

Respiratory Microbiota
Review article

Keynote series | Spotlight on managing health in obesity

Obesity
Video Series

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman

Prof. Jonette Keri

Developed by: Springer Medicine

Watch now

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Lipidomic signatures in Colombian adults with metabolic syndrome